Members of an advisory panel have proposed adding warning labels to some medication about adverse maternal and fetal risks in ...

EMA committee recommends marketing approval for Biogen’s Zurzuvae to treat women with postpartum depression: Cambridge, Massachusetts Monday, July 28, 2025, 17:00 Hrs [IST] Biog ...

Matrescence, or the transition to motherhood, changed everything about my identity and sense of self. Why aren't we talking ...

Obstetricians and psychiatrists are concerned about a recent FDA panel spreading misinformation about the potential harms of using SSRIs during pregnancy and postpartum.

For generations, women have relied on informal networks of friends, family and neighbors to navigate the complexities of ...

Just released, the 2025 Stanislaus County Community Health Assessment (CHA) provides an in-depth look at the health ...

UAMS said that postpartum mothers that used virtual visits to get health care were screened more often for specific risk ...

New mothers are often told to brace for an overwhelming rush of love, an instinctive bond. But what happens when the expected ...

At a recent FDA panel on SSRIs in pregnancy, the chair suggested rising antidepressant use may be contributing to — not ...

“In Chad, there’s a saying, ‘A woman who is pregnant has one foot in the grave,'” Angela Gorman, co-founder of the nonprofit ...

The CHMP’s recommendation for ZURZUVAE will now be reviewed by the EC for marketing authorization in the European Union with a final decision expected in the third quarter of 2025. The U.S. FDA ...

The FDA is spreading lies about medications people need—and starting their attack by targeting pregnant women.